NOL9

Across TCGA pan-cancer cohorts, NOL9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NOL9 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NOL9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NOL9 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, PDAC, and COAD are the cancer types where NOL9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.993	0.777	.002	32	view →
PDAC	DFS	Quartile	II,III,IV	0.333	0.620	.024	8	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
HNSC	OS	Quartile	III,IV	0.802	0.535	.009	4	view →
CCRCC	DFS	Median	All	0.658	0.809	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NOL9–LUAD (DFS)

Open the LUAD breakdown →